In vivo, SBI-457 reduced tumor burden and blocked sorafenib-driven nuclear accumulation of β-catenin, while in vitro screening revealed enhanced responses in HCC cell lines characterized by high soluble CXCL16 secretion and expression of a higher-molecular-weight CXCR6 isoform. This evidence concerns the gene CXCL16 and neoplasm.